Provided by Tiger Fintech (Singapore) Pte. Ltd.

uniQure NV

13.00
+3.6138.45%
Post-market: 13.240.2400+1.85%19:59 EDT
Volume:14.46M
Turnover:191.80M
Market Cap:703.00M
PE:-2.64
High:14.16
Open:13.01
Low:12.54
Close:9.39
Loading ...

Top Premarket Gainers

MT Newswires Live
·
17 Apr

UniQure Shares Soar After Latest FDA Designation for Huntington's Disease Treatment

Dow Jones
·
17 Apr

UniQure's Huntington's Drug Gets FDA Breakthrough Therapy Designation

MT Newswires Live
·
17 Apr

Uniqure Announces FDA Breakthrough Therapy Designation Granted To Amt-130 For The Treatment Of Huntington’S Disease

Reuters
·
17 Apr

uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease

GlobeNewswire
·
17 Apr

uniQure Is Maintained at Buy by Chardan Capital

Dow Jones
·
01 Apr

uniQure transferred with a Buy at Chardan

TIPRANKS
·
01 Apr

Analysts Have Conflicting Sentiments on These Healthcare Companies: AnaptysBio (ANAB), Cytokinetics (CYTK) and uniQure (QURE)

TIPRANKS
·
06 Mar

uniQure Price Target Maintained With a $70.00/Share by HC Wainwright & Co.

Dow Jones
·
05 Mar

uniQure Full Year 2024 Earnings: Misses Expectations

Simply Wall St.
·
01 Mar

uniQure Is Maintained at Equal-Weight by Wells Fargo

Dow Jones
·
01 Mar

Uniqure NV reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
27 Feb

uniQure (QURE) Receives a Buy from William Blair

TIPRANKS
·
27 Feb

UniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates

Zacks
·
27 Feb

uniQure FY 2024 GAAP EPS $(4.92) Misses $(3.99) Estimate, Sales $27.12M Miss $39.44M Estimate

Benzinga
·
27 Feb

uniQure Announces 2024 Financial Results and Highlights Recent Company Progress

GlobeNewswire
·
27 Feb

uniQure N.V. (NASDAQ:QURE) is a favorite amongst institutional investors who own 66%

Simply Wall St.
·
20 Feb

uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years

Benzinga
·
08 Feb

UniQure Advances AMT-191 Trial in Fabry Disease

MT Newswires Live
·
04 Feb

uniQure completes enrollment in first cohort of Phase I/IIa trial of AMT-191

TIPRANKS
·
03 Feb